| pubmed-article:8193369 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8193369 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8193369 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:8193369 | lifeskim:mentions | umls-concept:C0021745 | lld:lifeskim |
| pubmed-article:8193369 | lifeskim:mentions | umls-concept:C0040690 | lld:lifeskim |
| pubmed-article:8193369 | lifeskim:mentions | umls-concept:C0079189 | lld:lifeskim |
| pubmed-article:8193369 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:8193369 | lifeskim:mentions | umls-concept:C1155075 | lld:lifeskim |
| pubmed-article:8193369 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
| pubmed-article:8193369 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:8193369 | pubmed:dateCreated | 1994-6-27 | lld:pubmed |
| pubmed-article:8193369 | pubmed:abstractText | We have previously reported that transforming growth factor-beta 1 (TGF-beta 1) inhibits interleukin-6 (IL-6) induction by IL-2 and IL-1 in fresh human monocytes. We investigated the effects of TGF-beta 1 on the expression of tumoricidal activity induced by IL-2 or interferon-gamma (IFN-gamma) in human monocytes. We showed that TGF-beta 1 specifically inhibited, in a dose-dependent manner, IL-2-induced but not IFN-gamma-induced monocyte tumoricidal activity. The inhibitory effects of TGF-beta 1 on IL-2-activated monocytes were not caused by down-modulation of the IL-2 receptor beta (IL-2R beta) because the treatment of monocytes with IL-2 and TGF-beta 1 increased IL-2R beta mRNA expression. However, we found that TGF-beta 1 down-modulated IL-2-induced IL-2R gamma mRNA, which may be responsible for the TGF-beta 1 inhibition of monocyte activation by IL-2. The resistance of the IFN-gamma-induced activation to the inhibitory effects of TGF-beta 1 could be caused by the ability of IFN-gamma to decrease TGF-beta 1 receptor expression, as shown by cross-linking experiments. Overall, these results showed that TGF-beta 1 is a powerful inhibitor of IL-2- but not of IFN-gamma-induced activation of monocytes to a cytotoxic stage. This differential effect may be attributed to modulation of cytokine receptor expression. | lld:pubmed |
| pubmed-article:8193369 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8193369 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8193369 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8193369 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8193369 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8193369 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8193369 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8193369 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8193369 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8193369 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8193369 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:8193369 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:8193369 | pubmed:author | pubmed-author:LongoD LDL | lld:pubmed |
| pubmed-article:8193369 | pubmed:author | pubmed-author:RuscettiF WFW | lld:pubmed |
| pubmed-article:8193369 | pubmed:author | pubmed-author:VaresioLL | lld:pubmed |
| pubmed-article:8193369 | pubmed:author | pubmed-author:MoogFF | lld:pubmed |
| pubmed-article:8193369 | pubmed:author | pubmed-author:Espinoza-Delg... | lld:pubmed |
| pubmed-article:8193369 | pubmed:author | pubmed-author:MussoTT | lld:pubmed |
| pubmed-article:8193369 | pubmed:author | pubmed-author:BoscoM CMC | lld:pubmed |
| pubmed-article:8193369 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8193369 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:8193369 | pubmed:volume | 83 | lld:pubmed |
| pubmed-article:8193369 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8193369 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8193369 | pubmed:pagination | 3332-8 | lld:pubmed |
| pubmed-article:8193369 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:8193369 | pubmed:meshHeading | pubmed-meshheading:8193369-... | lld:pubmed |
| pubmed-article:8193369 | pubmed:meshHeading | pubmed-meshheading:8193369-... | lld:pubmed |
| pubmed-article:8193369 | pubmed:meshHeading | pubmed-meshheading:8193369-... | lld:pubmed |
| pubmed-article:8193369 | pubmed:meshHeading | pubmed-meshheading:8193369-... | lld:pubmed |
| pubmed-article:8193369 | pubmed:meshHeading | pubmed-meshheading:8193369-... | lld:pubmed |
| pubmed-article:8193369 | pubmed:meshHeading | pubmed-meshheading:8193369-... | lld:pubmed |
| pubmed-article:8193369 | pubmed:meshHeading | pubmed-meshheading:8193369-... | lld:pubmed |
| pubmed-article:8193369 | pubmed:meshHeading | pubmed-meshheading:8193369-... | lld:pubmed |
| pubmed-article:8193369 | pubmed:meshHeading | pubmed-meshheading:8193369-... | lld:pubmed |
| pubmed-article:8193369 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8193369 | pubmed:articleTitle | Inhibitory cytokine circuits involving transforming growth factor-beta, interferon-gamma, and interleukin-2 in human monocyte activation. | lld:pubmed |
| pubmed-article:8193369 | pubmed:affiliation | Medicine Branch, National Cancer Institute, Bethesda, MD. | lld:pubmed |
| pubmed-article:8193369 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8193369 | lld:pubmed |
